您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > ASP-4058
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ASP-4058
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ASP-4058图片
规格:98%
分子量:442.31
包装与价格:
包装价格(元)
250mg电议
500mg电议

产品介绍
ASP-4058是一个选择性的、口服活性的鞘氨醇磷酸受体1和5(S1P1andS1P5)的二代激动剂,能改善小鼠实验性自身免疫性脑脊髓炎,具有良好的安全性。
货号:ajcx12660
CAS:952565-91-2
分子式:C19H12F6N4O2
分子量:442.31
溶解度:Soluble in DMSO
纯度:98%
存储:Store at -20°C
库存:现货

Background:

ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile[1].


ASP4058 (p.o., daily for 21 days) reduces the clinical score in a dose-dependent manner and the cumulative clinical score from day 0 to 21 dpi at 0.03, 0.1 and 0.3 mg/kg are 15.5±1.48, 9.50±2.17 and 1.17±1.17, respectively, while that of vehicle-treated group is 15.5±0.619 in rats. ASP4058 prevents decreases in body weight of EAE rats[1].ASP4058 (p.o., daily for day 12 to day 45) maintains the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi) among the groups treated with 0.1 and 0.3 mg/kg dosages are 6.90±2.85 and 5.60±2.21, respectively in mice. The ED50 values for ASP4058 is 0.063 mg/kg[1].|| Animal Model:|Male Lewis rats with an induction of EAE[1].|Dosage:|0.03, 0.1 or 0.3 mg/kg.|Administration:|Oral administration once daily for 21 days.|Result:|Reduced the clinical score in a dose-dependent manner and the cumulative clinical score.|| Animal Model:|SJL mice immunized with PLP139-151 and boosted with pertussis toxin developed relapsing-remitting EAE[1].|Dosage:|0.1 and 0.3 mg/kg|Administration:|Oral administration once daily from day 12 to day 45.|Result:|Maintained the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi).

[1]. Rie Yamamoto, et al. ASP4058, a Novel Agonist for Sphingosine 1-Phosphate Receptors 1 and 5, Ameliorates Rodent Experimental Autoimmune Encephalomyelitis with a Favorable Safety Profile. PLoS One. 2014 Oct 27;9(10):e110819.